Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23258769 | 0.80 | ELANE (0.40) | SCN8ASCN10ASCN9A | |
| SCHEMBL23263854 | 0.80 | GAA (0.39) | BRD4MAPT | |
| SCHEMBL14839466 | 0.77 | ELANE (0.44) | HSPB1BRD4MAPT | |
| SCHEMBL23258826 | 0.76 | ELANE (0.41) | BRD4MAPTSCN8ASCN10A | |
| SCHEMBL2761277 | 0.74 | ELANE (0.49) | TRPA1SCN8ASCN10ASCN9A | |
| SCHEMBL23259156 | 0.72 | ELANE (0.40) | — | |
| SCHEMBL23249861 | 0.72 | HSPB1 (0.43) | HSPB1BRD4MAPTTRPA1 | |
| SCHEMBL23258558 | 0.70 | ELANE (0.40) | BRD4SCN8ASCN10A | |
| SCHEMBL23258536 | 0.70 | PKM (0.43) | BRD4MAPT | |
| SCHEMBL23258883 | 0.70 | ELANE (0.40) | BRD4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | KINESID THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | KINESID THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2021076945-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | TXNRD2, TXNRD1, SDHB | HSPB1 485/4885BRD4 4625/4885MAPT 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.